<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin J Traumatol</journal-id><journal-id journal-id-type="iso-abbrev">Chin. J. Traumatol</journal-id><journal-title-group><journal-title>Chinese Journal of Traumatology</journal-title></journal-title-group><issn pub-type="ppub">1008-1275</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28209450</article-id><article-id pub-id-type="pmc">5343096</article-id><article-id pub-id-type="publisher-id">S1008-1275(17)30014-7</article-id><article-id pub-id-type="doi">10.1016/j.cjtee.2016.02.005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of tranexamic acid in traumatic brain injury: A randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jokar</surname><given-names>Abolfazl</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Ahmadi</surname><given-names>Koorosh</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Tayyebeh</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Sharif-Alhoseini</surname><given-names>Mahdi</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Rahimi-Movaghar</surname><given-names>Vafa</given-names></name><email>v_rahimi@sina.tums.ac.ir</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Emergency Medicine, Arak University of Medical Science, Arak, Iran</aff><aff id="aff2"><label>b</label>Department of Emergency Medicine, Alborz University of Medical Sciences, Karaj, Iran</aff><aff id="aff3"><label>c</label>Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff4"><label>d</label>Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Sina Trauma and Surgery Research Center, Sina Hospital, Hassan-Abad Square, Imam Khomeini Ave, Tehran, 11365-3876, Iran. Fax: +98 216 6757009.Sina Trauma and Surgery Research CenterSina HospitalHassan-Abad SquareImam Khomeini AveTehran11365-3876Iran <email>v_rahimi@sina.tums.ac.ir</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>20</day><month>1</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>2</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>20</day><month>1</month><year>2017</year></pub-date><volume>20</volume><issue>1</issue><fpage>49</fpage><lpage>51</lpage><history><date date-type="received"><day>12</day><month>8</month><year>2015</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>1</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Production and hosting by Elsevier B.V.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Purpose</title><p>Traumatic brain injury (TBI) is a leading cause of death and disability. Intracranial hemorrhage (ICH) secondary to TBI is associated with a high risk of coagulopathy which leads to increasing risk of hemorrhage growth and higher mortality rate. Therefore, antifibrinolytic agents such as tranexamic acid (TA) might reduce traumatic ICH. The aim of the present study was to investigate the extent of ICH growth after TA administration in TBI patients.</p></sec><sec><title>Methods</title><p>This single-blind randomized controlled trial was conducted on patients with traumatic ICH (with less than 30&#x000a0;ml) referring to the emergency department of Vali-Asr Hospital, Arak, Iran in 2014. Patients, based on the inclusion and exclusion criteria, were divided into intervention and control groups (40 patients each). All patients received a conservative treatment for ICH, as well as either intravenous TA or placebo. The extent of ICH growth as the primary outcome was measured by brain CT scan after 48&#x000a0;h.</p></sec><sec><title>Results</title><p>Although brain CT scan showed a significant increase in hemorrhage volume in both groups after 48&#x000a0;h, it was significantly less in the TA group than in the control group (<italic>p</italic>&#x000a0;=&#x000a0;0.04). The mean total hemorrhage expansion was (1.7&#x000a0;&#x000b1;&#x000a0;9.7) ml and (4.3&#x000a0;&#x000b1;&#x000a0;12.9) ml in TA and placebo groups, respectively (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></sec><sec><title>Conclusion</title><p>It has been established that TA, as an effective hospital-based treatment for acute TBI, could reduce ICH growth. Larger studies are needed to compare the effectiveness of different doses.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Traumatic brain injuries</kwd><kwd>Intracranial hemorrhage</kwd><kwd>Traumatic</kwd><kwd>Tranexamic acid</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Traumatic brain injury (TBI) is a leading cause of death and disability. Each year about 1.5 million persons die and more than 10 million persons are hospitalized following a TBI worldwide.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> A study showed an annual incidence rate of 56.3/100,000 population for TBI in Tehran, Iran.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> One of the most important and devastating parts of the secondary pathologic cascade that may occur after the initial brain injury is the progression of intracranial hemorrhage (ICH), especially within the first 24&#x000a0;h.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Its frequency varies according to TBI severity.</p><p>ICH is also associated with a high risk of coagulopathy which leads to increased risk of hemorrhage growth and higher mortality.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Therefore the antifibrinolytics agents might reduce traumatic ICH. Tranexamic acid (TA), as an antifibrinolytic, has recently been shown to be an effective treatment of traumatic hemorrhage. In a recent mega-trial (CRASH-2) in more than 20,000 trauma patients with major bleeding, TA significantly reduced mortality, with no increase in vascular occlusive events.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Analysis of a TBI sub-group (<italic>n</italic>&#x000a0;=&#x000a0;270) showed a trend toward less mortality with TA.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> A systematic review demonstrated statistically significant reduction in ICH progression with TA and a non-statistically significant improvement of clinical outcomes in TBI patients.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> To date, there has been no study to determine the extent of ICH expansion after TA administration and also the optimal dose of TA in TBI patients. The present study aims to investigate the extent of ICH growth after TA administration in TBI patients.</p></sec><sec id="sec2"><title>Materials and methods</title><p>The patients with acute traumatic ICH were successively enrolled in this single-blinded, controlled, randomized trial at the emergency department of Vali-Asr Hospital, Arak, Iran in 2014. The study was approved by Research Ethics Committee, Arak University of Medical Sciences. The TBI patients aged 15 years and more, within 2&#x000a0;h of injury onset, and with acute ICH (volume of less than 30&#x000a0;ml) based on CT scan findings, were eligible for the trial. The exclusion criteria were: (1) Glasgow coma scale (GCS) total score &#x0003c;8; (2) unknown onset time; (3) ICH volume more than 30&#x000a0;ml as measured by CT scan; (4) need for surgery; (5) presence of focal neurologic deficits; (6) subarachnoid hemorrhage; (7) the cerebral edema with midline shift; (8) use of TA within the previous 14&#x000a0;d; (9) hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; (10) creatinine&#x000a0;&#x0003e;&#x000a0;20&#x000a0;mg/L; (11) pregnancy (women of child bearing potential must be tested); (12) history or current evidence suggestive of venous or arterial thrombotic events, including deep vein thrombosis, pulmonary emboli, cerebral vein thrombosis, cerebrovascular accident; (13) history of hypersensitivity to TA; and (14) history of acquired color blindness or visual vascular problems.</p><p>Informed consent was obtained from patients or their relative or representative. Initial brain CT scan was done immediately after admission and routine care. The baseline data including demographic data, mechanism of injury, and findings of initial brain CT scan (especially ICH volume) were entered. Then, included patients were randomized to get either the intervention or placebo treatment based on a computer-generated code list (40 patients in each group). Multiplicity adjustment was also done regarding to age, gender, and systolic blood pressure. All patients received a conservative treatment for ICH, and either intravenous TA (a bolus of 1&#x000a0;g in 100&#x000a0;ml 0.9% NaCl over 10&#x000a0;min followed by a continuous infusion of 1&#x000a0;g in 500&#x000a0;ml 0.9% NaCl over 8&#x000a0;h)<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> or unobvious placebo.</p><p>The extent of ICH growth as the primary outcome at 48&#x000a0;h after admission was measured by brain CT scan. We estimated a 60% rate of ICH growth in placebo patients, according to the previous studies.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> We planned to randomize 80 patients, 40 to each group. This trial would have about 80% power at the 0.05 level of significance (two-sided test) to distinguish a significant difference of 30% in the proportion of patients with ICH growth at 48&#x000a0;h.</p><p>An emergency medicine specialist who was blind to treatment allocation and clinical findings evaluated the first and second scans. Both baseline and 48&#x000a0;h ICH volumes were compared between treatment and placebo groups adjusted for baseline volume. Any intraventricular hemorrhage components were excluded in ICH volumes.</p></sec><sec id="sec3"><title>Results</title><p>We recruited 80 patients (40 allocated to TA and 40 allocated to placebo) in 2014. Baseline characteristics of the included patients are shown in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. Brain CT scan taken at 48&#x000a0;h after TBI showed a significant increase in hemorrhage volume in both groups (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). But the increased ICH volume in the TA group was significantly less than that in the control group (<italic>p</italic>&#x000a0;=&#x000a0;0.04, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). The mean total hemorrhage expansion was (1.7&#x000a0;&#x000b1;&#x000a0;9.7) ml and (4.3&#x000a0;&#x000b1;&#x000a0;12.9) ml in the TA and placebo groups, respectively (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></sec><sec id="sec4"><title>Discussion</title><p>Our study showed that TA could reduce ICH growth after TBI. Other studies demonstrated reduction in ICH progression, too.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref> The release of thromboplastin after TBI is followed by the activation of the coagulation and fibrinolytic pathways.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Increased fibrinolysis, distinguished by high levels of fibrinogen degradation products, is a main cause of coagulopathy in TBI, raising the probability that TA can decrease traumatic ICH.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Therefore, the earlier TA is administered, the more likely it will stop complete activation of fibrinolysis.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p><p>On the other hand, other studies demonstrated no improvement of clinical outcomes in TBI patients with TA.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib11" ref-type="bibr">11</xref> CRASH-2 collaborators although reported that TA significantly reduced all-cause mortality,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> in a subgroup analysis of traumatic ICH patients, TA showed non-significant trend to reduce mortality or dependency.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> They found that neither moderate benefits nor moderate harmful effects of TA can be excluded after TBI. Also, Harvey et&#x000a0;al<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> showed that there was no evidence of TA benefit in TBI patients. Valle et&#x000a0;al<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> reported that TA increased mortality in high injury acuity patients which can probably be attributed to the rapid availability of fluids and emergency operative interventions at the trauma centers.</p><p>In our study, the patients in TA group received two doses of TA (a bolus and a continuous infusion) as soon as possible after admission. The timing of TA administration and the existing status of the coagulation system (anticoagulation or procoagulation state) would determine whether thromboembolism formation is prevented or facilitated.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Gruen and Mitra<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> confirmed that the benefit was only seen when TA was administered within 3&#x000a0;h of injury. Also, Lipsky et&#x000a0;al<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> reported that sooner administration of TA improved the survival further. Valle et&#x000a0;al<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> reported that mortality associated with TA was influenced by the timing of administration.</p><p>In the present study, there was not any side effect of TA administration. Robert et&#x000a0;al<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> confirmed the safety of TA in a wide spectrum of patients with traumatic bleeding, even the most severely injured. A study showed that TA had no significant increase in serious prothrombotic complications if administered within 3&#x000a0;h of injury.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Zehtabchi et&#x000a0;al<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> declared the use of TA was not associated with significant (clinically or statistically) increase in the possibility of thromboembolic events compared with placebo or standard therapy in TBI.</p><p>There are some limitations that must be considered. This study was a single-blinded trial, whereas a double or triple-blinded trial would be more accurate. Meanwhile, the time period between trauma occurrence and TA administration had to be considered more precisely. Further, markers of coagulopathy were not measured. In conclusion, it has established that TA as an effective hospital-based treatment for acute TBI could reduce ICH growth. Larger studies are needed to compare the effectiveness of different doses.</p></sec><sec id="sec5"><title>Fund</title><p>This study was supported by <funding-source id="gs1">Arak University of Medical Sciences</funding-source> (Grant No. 806).</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>M.J.</given-names></name><name><surname>Roberts</surname><given-names>I.</given-names></name><name><surname>Perel</surname><given-names>P.</given-names></name></person-group><article-title>Patient outcome after traumatic brain injury in high-, middle- and low-income countries: analysis of data on 8927 patients in 46 countries</article-title><source>Int J Epidemiol</source><volume>38</volume><year>2009</year><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">18782898</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Rahimi-Movaghar</surname><given-names>V.</given-names></name><name><surname>Saadat</surname><given-names>S.</given-names></name><name><surname>Rasouli</surname><given-names>M.R.</given-names></name></person-group><article-title>The incidence of traumatic brain injury in Tehran, Iran: a population based study</article-title><source>Am Surg</source><volume>77</volume><year>2011</year><fpage>e112</fpage><lpage>e114</lpage><pub-id pub-id-type="pmid">21679621</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Specogna</surname><given-names>A.V.</given-names></name><name><surname>Turin</surname><given-names>T.C.</given-names></name><name><surname>Patten</surname><given-names>S.B.</given-names></name></person-group><article-title>Factors associated with early deterioration after spontaneous intracerebral hemorrhage: a systematic review and meta-analysis</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><fpage>e96743</fpage><pub-id pub-id-type="pmid">24809990</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.T.</given-names></name><name><surname>Ma</surname><given-names>B.T.</given-names></name></person-group><article-title>Prophylaxis against venous thromboembolism in orthopedic surgery</article-title><source>Chin J Traumatol</source><volume>9</volume><year>2006</year><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">16849000</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Williams-Johnson</surname><given-names>J.A.</given-names></name><name><surname>McDonald</surname><given-names>A.H.</given-names></name><name><surname>Strachan</surname><given-names>G.G.</given-names></name></person-group><article-title>Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial</article-title><source>West Indian Med J</source><volume>59</volume><year>2010</year><fpage>612</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">21702233</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><collab>CRASH-2 Collaborators</collab></person-group><article-title>Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study)</article-title><source>BMJ</source><volume>34</volume><year>2011</year><fpage>d37953</fpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Perel</surname><given-names>P.</given-names></name><name><surname>Al-Shahi Salman</surname><given-names>R.</given-names></name><name><surname>Kawahara</surname><given-names>T.</given-names></name></person-group><article-title>CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury&#x02014;a nested, randomised, placebo-controlled trial</article-title><source>Health Technol Assess</source><volume>16</volume><issue>iii-xii</issue><year>2012</year><fpage>1</fpage><lpage>54</lpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Zehtabchi</surname><given-names>S.</given-names></name><name><surname>Abdel Baki</surname><given-names>S.G.</given-names></name><name><surname>Falzon</surname><given-names>L.</given-names></name></person-group><article-title>Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis</article-title><source>Am J Emerg Med</source><volume>32</volume><year>2014</year><fpage>1503</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">25447601</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Dewan</surname><given-names>Y.</given-names></name><name><surname>Komolafe</surname><given-names>E.O.</given-names></name><name><surname>Mejia-Mantilla</surname><given-names>J.H.</given-names></name></person-group><article-title>CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial</article-title><source>Trials</source><volume>13</volume><year>2012</year><fpage>87</fpage><pub-id pub-id-type="pmid">22721545</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Meretoja</surname><given-names>A.</given-names></name><name><surname>Churilov</surname><given-names>L.</given-names></name><name><surname>Campbell</surname><given-names>B.C.</given-names></name></person-group><article-title>The spot sign and tranexamic acid on preventing ICH growth &#x02013; AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial</article-title><source>Int J Stroke</source><volume>9</volume><year>2014</year><fpage>519</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">23981692</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Yutthakasemsunt</surname><given-names>S.</given-names></name><name><surname>Kittiwatanagul</surname><given-names>W.</given-names></name><name><surname>Piyavechvirat</surname><given-names>P.</given-names></name></person-group><article-title>Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial</article-title><source>BMC Emerg Med</source><volume>13</volume><year>2013</year><fpage>20</fpage><pub-id pub-id-type="pmid">24267513</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>French</surname><given-names>K.F.</given-names></name><name><surname>White</surname><given-names>J.</given-names></name><name><surname>Hoesch</surname><given-names>R.E.</given-names></name></person-group><article-title>Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator</article-title><source>Neurocrit Care</source><volume>17</volume><year>2012</year><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">22311234</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Nakae</surname><given-names>R.</given-names></name><name><surname>Takayama</surname><given-names>Y.</given-names></name><name><surname>Kuwamoto</surname><given-names>K.</given-names></name></person-group><article-title>Time course of coagulation and fibrinolytic parameters in patients with traumatic brain injury</article-title><source>J&#x000a0;Neurotrauma</source><volume>33</volume><year>2016</year><fpage>688</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">26414158</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>D.S.</given-names></name><name><surname>Mitra</surname><given-names>B.</given-names></name><name><surname>Cameron</surname><given-names>P.A.</given-names></name></person-group><article-title>Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: definition, incidence and outcomes</article-title><source>Br J Neurosurg</source><year>2014</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Gruen</surname><given-names>R.L.</given-names></name><name><surname>Mitra</surname><given-names>B.</given-names></name></person-group><article-title>Tranexamic acid for trauma</article-title><source>Lancet</source><volume>377</volume><year>2011</year><fpage>1052</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">21439636</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>V.</given-names></name><name><surname>Perrone</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>P.</given-names></name></person-group><article-title>Does the use of tranexamic acid improve trauma mortality?</article-title><source>Ann Emerg Med</source><volume>63</volume><year>2014</year><fpage>460</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">24095056</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Valle</surname><given-names>E.J.</given-names></name><name><surname>Allen</surname><given-names>C.J.</given-names></name><name><surname>VanHaren</surname><given-names>R.M.</given-names></name></person-group><article-title>Do all trauma patients benefit from tranexamic acid?</article-title><source>J&#x000a0;Trauma Acute Care Surg</source><volume>76</volume><year>2014</year><fpage>1373</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">24854303</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Zehtabchi</surname><given-names>S.</given-names></name><name><surname>Abdel Baki</surname><given-names>S.G.</given-names></name><name><surname>Falzon</surname><given-names>L.</given-names></name></person-group><article-title>Tranexamic acid in brain injury: devil in the detail</article-title><source>Am J Emerg Med</source><volume>33</volume><year>2015</year><fpage>458</fpage></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Lipsky</surname><given-names>A.M.</given-names></name><name><surname>Abramovich</surname><given-names>A.</given-names></name><name><surname>Nadler</surname><given-names>R.</given-names></name></person-group><article-title>Tranexamic acid in the prehospital setting: Israel Defense Forces' initial experience</article-title><source>Injury</source><volume>45</volume><year>2014</year><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">24074828</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>I.</given-names></name><name><surname>Perel</surname><given-names>P.</given-names></name><name><surname>Prieto-Merino</surname><given-names>D.</given-names></name></person-group><article-title>Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial</article-title><source>BMJ</source><volume>345</volume><year>2012</year><fpage>e5839</fpage><pub-id pub-id-type="pmid">22968527</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgment</title><p>The authors would like to thank Mrs. Bita Pourmand (Research Development Center, Sina Hospital, Tehran University of Medical Sciences) for her precious edit of the manuscript.</p></ack><fn-group><fn id="d31e224"><p id="ntpara0010">Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.</p></fn></fn-group></back><floats-group><table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of patients with ICH who were allocated to TA or placebo groups.</p></caption><alt-text id="alttext0010">Table&#x000a0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>TA (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th>Placebo (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="3">Gender&#x02217;</td><td>0.30</td></tr><tr><td>&#x000a0;Male</td><td>32 (40.0)</td><td>28 (35.0)</td><td rowspan="2"/></tr><tr><td>&#x000a0;Female</td><td>8 (10.0)</td><td>12 (15.0)</td></tr><tr><td>Age: mean&#x000a0;&#x000b1;&#x000a0;SD (years)</td><td>35.4&#x000a0;&#x000b1;&#x000a0;14.6</td><td>36.2&#x000a0;&#x000b1;&#x000a0;14.9</td><td>0.79</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>160.1&#x000a0;&#x000b1;&#x000a0;21.1</td><td>161.9&#x000a0;&#x000b1;&#x000a0;18.1</td><td>0.68</td></tr><tr><td>Initial ICH volume (ml)</td><td>21.6&#x000a0;&#x000b1;&#x000a0;5.37</td><td>22.2&#x000a0;&#x000b1;&#x000a0;4.9</td><td>0.83</td></tr><tr><td colspan="3">ICH type&#x02217;</td><td>0.83</td></tr><tr><td>&#x000a0;Epidural hematoma</td><td>6 (7.5)</td><td>6 (7.5)</td><td rowspan="3"/></tr><tr><td>&#x000a0;Subdural hematoma</td><td>6 (7.5)</td><td>8 (10.0)</td></tr><tr><td>&#x000a0;Cerebral hematoma</td><td>28 (35.0)</td><td>26 (32.5)</td></tr><tr><td colspan="3">Hospital stay days&#x02217;</td><td>0.15</td></tr><tr><td>&#x000a0;&#x0003c;15</td><td>28 (35.0)</td><td>22 (27.4)</td><td rowspan="3"/></tr><tr><td>&#x000a0;15&#x02013;30</td><td>9 (11.3)</td><td>9 (11.3)</td></tr><tr><td>&#x000a0;&#x0003e;30</td><td>3 (3.7)</td><td>9 (11.3)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Note: ICH: intracranial hemorrhage; TA: tranexamic acid.</p></fn><fn id="tspara0030"><p>&#x02217;: Data are expressed as <italic>n</italic> (%).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Effect of TA on total hemorrhage expansion in the patients with ICH in two groups.</p></caption><alt-text id="alttext0015">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Group</th><th colspan="3">ICH volume (ml)<hr/></th></tr><tr><th>Initial</th><th>After 48&#x000a0;h</th><th>Expansion</th></tr></thead><tbody><tr><td>TA</td><td>21.6&#x000a0;&#x000b1;&#x000a0;5.37</td><td>23.3&#x000a0;&#x000b1;&#x000a0;6.4</td><td>1.7&#x000a0;&#x000b1;&#x000a0;9.7</td></tr><tr><td>Placebo</td><td>22.2&#x000a0;&#x000b1;&#x000a0;4.9</td><td>26.5&#x000a0;&#x000b1;&#x000a0;6.4</td><td>4.3&#x000a0;&#x000b1;&#x000a0;12.9</td></tr><tr><td><italic>p</italic> value</td><td>0.83</td><td>0.04</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Note: ICH: intracranial hemorrhage; TA: tranexamic acid.</p></fn></table-wrap-foot></table-wrap></floats-group></article>